Mobile

A double-blind, placebo controlled, randomized, two centre phase IIa pharmacodynamic cross-over study to assess the effect of AZD3355, 65 mg bid, on transient lower esophageal sphincter relaxations (T...

Mise à jour : Il y a 4 ans
Référence : EUCTR2006-004501-25

A double-blind, placebo controlled, randomized, two centre phase IIa pharmacodynamic cross-over study to assess the effect of AZD3355, 65 mg bid, on transient lower esophageal sphincter relaxations (TLESRs) in GERD patients with incomplete response to PPI

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to assess the effect of repeated oral administration of AZD3355, 65 mg bid, measured as reduction in the number of transient lower esophageal sphincter relaxations (TLESRs), compared to placebo during 4 hours post third dose.

Critère d'inclusion

  • gastroesophageal reflux disease:GERD

Liens